Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company provides the research and development of tumor-targeted drugs in China in globally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).

It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. Founded in 2004, the company is based in Shanghai, China.